Skip to content
ES
MARKETS / NASDAQ / TCMD
NASDAQ · SURGICAL & MEDICAL INSTRUMENTS & APPARATUS · MID CAP

Tactile Systems Technology Inc. TCMD

12 fiscal years on record · USD · FY2025 reported · SEC filings only
$329.5M
▲ 12.5% YoY
$19.1M
▲ 12.5% YoY
$40.4M
▲ 5.7% YoY
In brief

What this company does

Tactile Systems Technology, Inc. develops and provides medical devices for the treatment of underserved chronic diseases. For the year ended December 31, 2025, it generated revenue of $329.5 million and net income of $19.1 million. As of December 31, 2025, it employed 166 account managers and 166 specialists supporting its lymphedema products, and a team of 19 specialists supporting its airway clearance products. Its therapeutic focus areas are vascular disease, aimed at treating lymphedema and chronic venous insufficiency; oncology, where lymphedema is a common consequence among cancer survivors; and airway clearance therapy for people with chronic respiratory conditions. Sales and rentals of its lymphedema products generated $278.4 million, or 84% of revenue, in 2025. The AffloVest product line generated $51.1 million, or 16% of revenue, in 2025. Tactile Systems Technology, Inc. was originally incorporated in Minnesota on January 30, 1995.

Written from the business description in TACTILE SYSTEMS TECHNOLOGY INC's annual report to the U.S. Securities and Exchange Commission, filed 17 February 2026. Every sentence was checked against that document before publication.

Growth
USD 329.5M
Revenue, FY2025 · full 12-year series below
Revenue $M Net income $M
FY2025 · Revenue 329.5 · Net income 19.1
200M2014201620182020202220242025
Compound annual growth
+10.1%
+12.0%
+18.0%
+29.9%
3 yrs
5 yrs
10 yrs
15 yrs

Revenue compounded at +12.0% a year over five years.

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability
6 cents
of every revenue dollar became profit
Operating margin Net margin
FY2025 · Operating 8.9% · Net 5.8%
5%10%-2%-4%-6%2014201620182020202220242025
ROE
FY2025 · ROE 8.8%
5%10%15%-5%-10%2014201620182020202220242025
Gross margin75.9%
Operating margin8.9%
Net margin5.8%
Return on assets6.7%
EBITDAUSD 35.9M

Each USD of equity produced 9 cents of profit this year.

Cash & shareholders
USD 26.3M
returned in FY2025 · dividends + net buybacks
Free cash flow $M
FY2025 · FCF 40.4
20M40M2014201620182020202220242025
Net buybacks $M Dividends $M
FY2025 · Dividends — · Net buybacks 26.3
10M20M201720242025
Dividends paid—
Net buybacksUSD 26.3M
Share of profit138.0%
Consecutive raises—

USD 26.3M in buybacks — 138% of the year's profit, so the payout drew on cash built up earlier.

Total assetsUSD 273.9M
EquityUSD 218.9M
CashUSD 83.4M
Gross debtUSD 0.00
Net debtUSD -83.4M
Current ratio4.03×

The company holds more cash than debt.

The 12-year record
12 fiscal years
Every figure from documents filed with the SEC · USD

EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.

row low → row highnegative
Metric 202520242023202220212020201920182017201620152014
Revenue $B0.30.30.30.20.20.20.20.10.10.10.10.0
Operating income $B0.00.00.0−0.0−0.0−0.00.00.00.00.00.00.0
EBITDA $B0.00.00.0−0.00.0−0.00.00.00.00.00.00.0
Income tax $B0.00.0−0.00.00.0−0.00.0−0.0−0.00.00.00.0
Net income $B0.00.00.0−0.0−0.0−0.00.00.00.00.00.00.0
Free cash flow $B0.00.00.00.00.00.0−0.00.00.00.00.0−0.0
EPS, diluted $0.820.701.23−0.89−0.60−0.030.560.340.310.15−0.150.02
Dividend / sh $············
Payout %············
ROE %8.88.318.1−14.3−9.3−0.510.98.28.810.7··
Shares out B0.020.020.020.020.020.020.020.020.020.020.00·

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

Provenance
Company facts, as filed
How we verify · 0 failures in 58 reconciliationsAUDITED

Reconciled in 12 of 19 fiscal years. 37 checks could not be computed.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquiditymoeda_consistente0 failures
ActivitySurgical & Medical Instruments & Apparatus
Listed onNASDAQ
Incorporated inMinnesota
Fiscal year endsDecember 31
Data on record since2014

Share this section

Download image